Venus gets European patent for antibiotic drug

Drug major Venus Remedies today said its research arm Venus Medicine Research Centre has received patent for its antibiotic product 'VRP008' from European Patent Office (EPO).
The product is designed for mixed multi-drug infections for pediatric, geriatric and adult immuno-compromised patients where the risk of adverse events is high and very low amount of doses are required, Panchkula-based company said in a statement issued here today.
"Once launched, VRP008 (research code for this Antibiotic Adjuvant Entity) will be one of the best solutions for ICU infections," said Manu Chaudhary, Joint Managing Director cum Director Research, Venus Remedies Limited.
This product, which consists of a carbapenem and a novel amino glycoside, is the outcome of the eight years of research and it is developed by following stringent international guidelines defined for developing a new drug and has undergone for pre-clinical studies such as Acute Toxicity, Sub Acute toxicity, Intravenous, para venous toxicities as per OECD guidelines, the statement said.

At present, at least 25,000 people die each year in the European Union from infections due to 'Eskape' pathogens which are multi-drug-resistant organisms.
Infections caused by these antibiotic-resistant bacteria resulted in approximately 2.5 million extra hospital days annually in Europe.
Venus has already received EU patent for its product Elores, Potentox, Vancoplus and Achnil.